

REGULATION OF HUMAN LYMPH CONTRACTILITY BY PROSTAGLANDINS AND THROMBOXANE

Helmut Sinzinger, M.D., Josef Kaliman, M.D. and Eva Manheimer, M.D.

Departments of Medical Physiology, Nuclear Medicine and Cardiology, University of Vienna, Austria

ABSTRACT:

Thromboxane A₂ (TXA₂), but not prostacyclin (PGI₂), plays an important role in human lymph vessel contraction. Paradoxically, whereas substantial amounts of PGI₂ are detectable in human lymphatics, TXA₂ is undetectable and probably derives from surrounding tissues.

Since the discovery of prostacyclin (PGI₂) this endogenously formed intermediate of arachidonic acid metabolism has been implicated as an important regulator of vascular tone and contractility (1). While information about prostaglandins (PG) in relation to lymphatics is limited, it is now known that human lymphatics generate significant amounts of PGI₂ (2,3). In a companion paper (4) we describe a clearer profile of prostaglandin synthesis in human lymphatics. However, thromboxane A₂, which reportedly contracts sheep and bovine lymph vessels (5), is undetectable. In this report we examine whether human lymph vessels resemble animal species in their response to arachidonic acid derivatives.

MATERIALS AND METHODS

We investigated 5 human lymphatics from 4 males and 1 female aged 15 to 47 years. The lymphatics were cut into rings with a circumference of about 5mm. Two wires were fixed via the lumen as described by Johnston and Gordon (5). The lower one was fixed to the bottom of a 5ml perfusion bath while the upper one was connected with an isometric transducer (Har-

vard Instruments) to a recorder (Pharmacia). The vessels were perfused with an oxygenated (95% O₂, 5% CO₂) Krebs-Ringer solution kept at a constant temperature of 37°C. The tension the vessels were placed under amounted to 0.5 g. PGH₂ was dissolved in the Krebs solution containing the lymph vessel. Thromboxane synthetase was inhibited by imidazole and a specific thromboxane synthetase inhibitor. Prostacyclin and PGE₁ were added to the Krebs-Ringer bath immediately prior to the experiment. Before beginning the experiment, the lymphatics were kept at a constant tension for at least 60 minutes in order to allow for "equilibration".

RESULTS

In the concentration range used little or no effect of PGI₂ or PGE₁ on lymphatic tone was detected (Fig. 1). In contrast, in the resting lymphatic vessel, PGH₂ exerted in a low nano-range concentration a sharp increase in tone. In the presence of imidazole this response was less prominent. Addition of phentolamine and methysergide in micro-range concentration failed to inhibit spontaneous rhythmic contraction of lymphatics.

DISCUSSION

Prostaglandins exert various effects on the vascular system. PGE₁ causes either contraction or relaxation (6) depending on site and dosage. PGI₂ also functions as a

contractile (7), biphasic (8,9), or relaxing agent (10,11). Results vary depending on vessels from different species, whether arteries or veins are examined and the site of testing (12-14). Johnston and Gordon (5) showed that TXA_2 and PGH_2 both contract lymphatics and extensive pharmacological testing confirms that these substances are important contractile stimulants for lymph vessels. In addition, these workers demonstrated that bovine and sheep lymph vessels in vitro convert PGH_2 to TXA_2 with a much stronger contractile effect. In contrast, examination of arachidonic acid metabolic profile more or less excludes an important synthesis and conversion to TXA_2 at least under in vitro conditions. On the other hand, as Fig. 1 demonstrates with inhibition of thromboxane synthetase or conversion of PGH_2 to TXA_2 by imidazole the contractile response of human lymphatics is partially suppressed. As various prostanoids are detectable in high concentrations in lymphatics (15), especially with inflammation, prostaglandins are likely an important modulator of

lymphatic tone (16). Although Johnston and Gordon (5) demonstrated that important contractile stimulants to lymphatics are PGH_2 and TXA_2 and these findings are supported by lack of interference of lymphatic contractility in our study by the vasoactive drugs methysergide (serotonin antagonist) and phentolamine (adrenergic antagonist), the role of PGI_2 which is synthesized in substantial amounts in vessel walls (2,3) is less clear. Together these findings suggest key roles for both PGH_2 and TXA_2 in human lymphatic contractility, although the origin of TXA_2 is probably extralymphatic.

H. Sinzinger M.D., ASF, Schwarzschanerstrasse 17, A 1090 Vienna, Austria
 Eva Mannheimer, M.D., Prof., Dept. of Cardiology, University of Vienna, Garnisonsgasse 13, A-1090 Vienna, Austria
 J. Kaliman, M.D., Dept. of Cardiology, University of Vienna, Garnisonsgasse 13, A-1090 Vienna, Austria




Figure 1: Effect of various prostaglandins in different doses on contractility of human lymph vessels. Below 0 line represents relaxation or "negative" contraction.

REFERENCES

1. Moncada, S, RJ Gryglewski, S Bunting, et al: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. *Nature* 263 (1976), 663-665.
2. Mannheimer, E, H Sinzinger, R Oppolzer, et al: Prostacyclin Synthesis in Human Lymphatics. *Lymphology* 13 (1980), 44-46.
3. Mannheimer, E, H Sinzinger, R Oppolzer, et al: Prostacyclinsynthese in menschlichen Lymphgefäßen. *Angioarchiv.* 1 (1981), 19.
4. Sinzinger, H, J Kaliman, E Mannheimer: Arachidonic acid metabolites of human lymphatics. *Lymphology* 17(1984), 39-42
5. Johnston, MG, JL Gordon: Regulation of lymphatic contractility by arachidonic acid metabolites. *Nature* 293 (1981), 294-297.
6. Rioux, F, G Gagnon, P Regoli: Stimulating actions of various prostaglandins and noradrenalin in strips of rabbit renal artery. *Canad. J. Physiol.* 56 (1978), 321-323.
7. Levy, SV: Contractile response to prostacyclin (PGI_2) of isolated human saphenous and rat venous tissue. *Prostaglandins* 16 (1978), 93-97.
8. Manku, MS, DF Horrobin, AI Cunnane, et al: Prostaglandin E_1 , E_2 and I_2 : Evidence for three distinct actions in vascular smooth muscle. *Biochem. Biophys. Res. Commun.* 83 (1978), 295.
9. Pomerantz, KP, AL Sintetos, PW Ramwell: The effect of prostacyclin on the human umbilical artery. *Prostaglandins* 15 (1978), 1035-1044.
10. Dusting, GJ, S Moncada, JR Vane: Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries in induced by arachidonic acid. *Prostaglandins* 13 (1977), 3-16.
11. Ogeltree, ML, JB Smith, AM Lefer: Actions of prostaglandins on isolated perfused rat coronary arteries. *Am. J. Physiol.* 235 (1978), 400-406.
12. Bunting, S, RJ Gryglewski, S Moncada, et al: Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and arteries and inhibits platelet aggregation. *Prostaglandins* 12 (1976), 897-913.
13. Goldberg, MR, VS Herbert, PJ Katowitz: Effects of prostaglandins and endoperoxides analogs on canine saphenous vein. *Am. J. Physiol.* 233 (1977), 361-368.
14. Strong, CG, DF Bohr: Effects of prostaglandin E_1 , E_2 , A_2 and F on isolated vascular smooth muscle. *Am. J. Physiol.* 213 (1967), 275-283.
15. Johnston, MG, JB Hay, HZ Movat: Kinetics of prostaglandin production in various inflammatory lesions, measured in draining lymph. *Am. J. Pathol.* 95 (1979), 225-238.
16. Okhashi, T, Y Kawai, T Azmna: The response of lymphatic smooth muscles to vasoactive substances. *Eur. J. Pharm.* 375 (1978), 183-188.